<mods:mods version="3.3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" xmlns:mods="http://www.loc.gov/mods/v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><mods:titleInfo><mods:title>SUT BEZI SARATONI KASALLIGINI KIMYOTERAPIYA BILAN DAVOLASHNING YUTUQ VA KAMCHILIKLARI</mods:title></mods:titleInfo><mods:name type="personal"><mods:namePart type="given">Jumayev M. Yu</mods:namePart><mods:namePart type="family">Jumayev M. Yu</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:name type="personal"><mods:namePart type="given">Xayitova G. A</mods:namePart><mods:namePart type="family">Xayitova G. A</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:name type="personal"><mods:namePart type="given">Xalilova  X. A</mods:namePart><mods:namePart type="family">Xalilova  X. A</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:abstract>Sut bezi saratoni (SBS) ayollar orasida eng ko‘p uchraydigan onkologik kasallik bo‘lib, global o‘lim sabablaridan biri hisoblanadi. Kimyoterapiya kasallikning erta va rivojlangan bosqichlarida muhim davolash usuli sifatida qo‘llaniladi. Ayniqsa, antrasiklinlar, taksanlar va platina asosidagi preparatlar adjuvant, neoadjuvant hamda metastatik bosqichlarda samarali hisoblanadi. Ushbu maqolada kimyoterapiyaning klinik samaradorligi, omon qolish ko‘rsatkichlariga ta’siri hamda nojo‘ya ta’sirlari tahlil qilinadi.</mods:abstract><mods:originInfo><mods:dateIssued encoding="iso8601">2026-03-29</mods:dateIssued></mods:originInfo><mods:genre>Maqola</mods:genre></mods:mods>